Drug intelligence / Profile preview

Fosdevirine

Development stage: Phase 2
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Fosdevirine is an experimental antiviral agent classified as a non-nucleoside reverse transcriptase inhibitor (NNRTI). It was developed for the treatment of HIV/AIDS and demonstrated potent activity against both wild-type and efavirenz-resistant strains of HIV-1. Fosdevirine was discovered by Idenix Pharmaceuticals and further developed by GlaxoSmithKline and ViiV Healthcare. Clinical development reached Phase 2 but was discontinued due to unexpected delayed-onset seizures observed in some patients[1][3][5][7].

Other names: 1018450-26-4UNII-Z4I0C281BJUNII-Z-4I0C281BJUNII-Z 4I0C281BJ

Targets

GABRR (GABA-A receptor subunit rho)Human immunodeficiency virus type 1 reverse transcriptase

Beyond the preview

Go deeper on Fosdevirine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fosdevirine.

Explore the full profile